PMID- 24586351 OWN - NLM STAT- MEDLINE DCOM- 20150102 LR - 20211203 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 9 IP - 2 DP - 2014 TI - Comparable autoantibody serum levels against amyloid- and inflammation-associated proteins in Parkinson's disease patients and controls. PG - e88604 LID - 10.1371/journal.pone.0088604 [doi] LID - e88604 AB - Naturally occurring autoantibodies (NAbs) against a number of potentially disease-associated cellular proteins, including Amyloid-beta1-42 (Abeta1-42), Alpha-synuclein (Asyn), myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), and S100 calcium binding protein B (S100B) have been suggested to be associated with neurodegenerative disorders, in particular Alzheimer's (AD) and Parkinson's disease (PD). Whereas the (reduced) occurrence of specific NAbs in AD is widely accepted, previous literature examining the relation of these NAb titres between PD patients and controls, as well as comparing these levels with demographic and clinical parameters in PD patients have produced inconsistent findings. We therefore aimed, in a cross-sectional approach, to determine serum titres of the above NAbs in a cohort of 93 PD patients (31 of them demented) and 194 controls. Levels were correlated with demographic and clinical variables, cerebrospinal fluid Abeta1-42, total tau and phospho-tau levels, as well as with single nucleotide polymorphisms (SNPs) of genes which either have been reported to influence the immune system, the amyloid cascade or the occurrence of PD (ApoE, GSK3B, HLA-DRA, HSPA5, SNCA, and STK39). The investigated NAb titres were neither significantly associated with the occurrence of PD, nor with demographic and clinical parameters, neurodegenerative markers or genetic variables. These results argue against a major potential of blood-borne parameters of the adaptive immune system to serve as trait or state markers in PD. FAU - Maetzler, Walter AU - Maetzler W AD - Center of Neurology, Department of Neurodegeneration and Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany ; DZNE, German Center for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany. FAU - Apel, Anja AU - Apel A AD - Center of Neurology, Department of Neurodegeneration and Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany ; DZNE, German Center for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany. FAU - Langkamp, Markus AU - Langkamp M AD - Mediagnost, Reutlingen, Germany. FAU - Deuschle, Christian AU - Deuschle C AD - Center of Neurology, Department of Neurodegeneration and Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany ; DZNE, German Center for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany. FAU - Dilger, Sarah Selina AU - Dilger SS AD - Center of Neurology, Department of Neurodegeneration and Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany ; DZNE, German Center for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany. FAU - Stirnkorb, Johannes Georg AU - Stirnkorb JG AD - Center of Neurology, Department of Neurodegeneration and Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany ; DZNE, German Center for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany. FAU - Schulte, Claudia AU - Schulte C AD - Center of Neurology, Department of Neurodegeneration and Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany ; DZNE, German Center for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany. FAU - Schleicher, Erwin AU - Schleicher E AD - Department of Internal Medicine IV, University Hospital Tuebingen, Tuebingen, Germany. FAU - Gasser, Thomas AU - Gasser T AD - Center of Neurology, Department of Neurodegeneration and Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany ; DZNE, German Center for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany. FAU - Berg, Daniela AU - Berg D AD - Center of Neurology, Department of Neurodegeneration and Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany ; DZNE, German Center for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany. LA - eng PT - Journal Article DEP - 20140221 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Amyloid beta-Peptides) RN - 0 (Apolipoproteins E) RN - 0 (Autoantibodies) RN - 0 (Endoplasmic Reticulum Chaperone BiP) RN - 0 (HLA-DR alpha-Chains) RN - 0 (HSPA5 protein, human) RN - 0 (Heat-Shock Proteins) RN - 0 (Myelin Basic Protein) RN - 0 (Myelin-Oligodendrocyte Glycoprotein) RN - 0 (S100 Calcium Binding Protein beta Subunit) RN - 0 (SNCA protein, human) RN - 0 (alpha-Synuclein) RN - EC 2.7.11.1 (GSK3B protein, human) RN - EC 2.7.11.1 (Glycogen Synthase Kinase 3 beta) RN - EC 2.7.11.1 (Protein Serine-Threonine Kinases) RN - EC 2.7.11.1 (STK39 protein, human) RN - EC 2.7.11.26 (Glycogen Synthase Kinase 3) SB - IM MH - Amyloid beta-Peptides/blood/*immunology MH - Apolipoproteins E/genetics MH - Autoantibodies/*blood MH - Case-Control Studies MH - Cross-Sectional Studies MH - Endoplasmic Reticulum Chaperone BiP MH - Enzyme-Linked Immunosorbent Assay MH - Glycogen Synthase Kinase 3/genetics MH - Glycogen Synthase Kinase 3 beta MH - HLA-DR alpha-Chains/genetics MH - Heat-Shock Proteins/genetics MH - Humans MH - Myelin Basic Protein/blood/*immunology MH - Myelin-Oligodendrocyte Glycoprotein/blood/*immunology MH - Parkinson Disease/blood/*immunology MH - Polymorphism, Single Nucleotide/genetics MH - Protein Serine-Threonine Kinases/genetics MH - S100 Calcium Binding Protein beta Subunit/blood/*immunology MH - Statistics, Nonparametric MH - alpha-Synuclein/blood/genetics/*immunology PMC - PMC3931625 COIS- Competing Interests: One of the authors (Markus Langkamp) is employed by a commercial company (Mediagnost, Reutlingen, Germany). There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials. EDAT- 2014/03/04 06:00 MHDA- 2015/01/03 06:00 PMCR- 2014/02/21 CRDT- 2014/03/04 06:00 PHST- 2013/10/04 00:00 [received] PHST- 2014/01/10 00:00 [accepted] PHST- 2014/03/04 06:00 [entrez] PHST- 2014/03/04 06:00 [pubmed] PHST- 2015/01/03 06:00 [medline] PHST- 2014/02/21 00:00 [pmc-release] AID - PONE-D-13-40642 [pii] AID - 10.1371/journal.pone.0088604 [doi] PST - epublish SO - PLoS One. 2014 Feb 21;9(2):e88604. doi: 10.1371/journal.pone.0088604. eCollection 2014.